{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:34:25Z","timestamp":1792859665408,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94740-5","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T14:23:49Z","timestamp":1742394229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Financial burden of out of pocket nonpharmacological therapies in an Austrian multiple sclerosis cohort"],"prefix":"10.1038","volume":"15","author":[{"given":"Tiago","family":"Lerda Casaccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hefner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Bieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kliushnikova","family":"Dariia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hitzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wipfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"94740_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson, R. & Giovannoni, G. Multiple sclerosis\u2014A review. Eur. J. Neurol. 26, 27\u201340. https:\/\/doi.org\/10.1111\/ene.13819 (2019).","journal-title":"Eur. J. Neurol."},{"key":"94740_CR2","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/jnnp.2006.090365","volume":"77","author":"G Kobelt","year":"2006","unstructured":"Kobelt, G., Berg, J., Lindgren, P., Fredrikson, S. & Jonsson, B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry 77, 918\u2013926. https:\/\/doi.org\/10.1136\/jnnp.2006.090365 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"94740_CR3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1212\/WNL.0000000000000250","volume":"82","author":"V Yadav","year":"2014","unstructured":"Yadav, V. et al. Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology 82, 1083\u20131092. https:\/\/doi.org\/10.1212\/WNL.0000000000000250 (2014).","journal-title":"Neurology"},{"key":"94740_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12906-018-2342-2","volume":"18","author":"J Mbizo","year":"2018","unstructured":"Mbizo, J. et al. Complementary and alternative medicine use among persons with multiple chronic conditions: Results from the 2012 National Health Interview Survey. BMC Complement Altern. Med. 18, 281. https:\/\/doi.org\/10.1186\/s12906-018-2342-2 (2018).","journal-title":"BMC Complement Altern. Med."},{"key":"94740_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/jnnp-2016-314490","volume":"89","author":"SB Claflin","year":"2018","unstructured":"Claflin, S. B., van der Mei, I. A. F. & Taylor, B. V. Complementary and alternative treatments of multiple sclerosis: A review of the evidence from 2001 to 2016. J. Neurol. Neurosurg. Psychiatry 89, 34\u201341. https:\/\/doi.org\/10.1136\/jnnp-2016-314490 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"94740_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00415-011-6226-3","volume":"259","author":"K O'Connor","year":"2012","unstructured":"O\u2019Connor, K. et al. Patterns of dietary and herbal supplement use by multiple sclerosis patients. J. Neurol. 259, 637\u2013644. https:\/\/doi.org\/10.1007\/s00415-011-6226-3 (2012).","journal-title":"J. Neurol."},{"key":"94740_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ctim.2017.12.006","volume":"36","author":"M Gotta","year":"2018","unstructured":"Gotta, M., Mayer, C. A. & Huebner, J. Use of complementary and alternative medicine in patients with multiple sclerosis in Germany. Complement Ther. Med. 36, 113\u2013117. https:\/\/doi.org\/10.1016\/j.ctim.2017.12.006 (2018).","journal-title":"Complement Ther. Med."},{"key":"94740_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1191\/0269215503cr604oa","volume":"17","author":"S Nayak","year":"2003","unstructured":"Nayak, S., Matheis, R. J., Schoenberger, N. E. & Shiflett, S. C. Use of unconventional therapies by individuals with multiple sclerosis. Clin. Rehabil. 17, 181\u2013191. https:\/\/doi.org\/10.1191\/0269215503cr604oa (2003).","journal-title":"Clin. Rehabil."},{"key":"94740_CR9","doi-asserted-by":"publisher","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","volume":"98","author":"B Bebo","year":"2022","unstructured":"Bebo, B. et al. The economic burden of multiple sclerosis in the united states: Estimate of direct and indirect costs. Neurology 98, e1810\u2013e1817. https:\/\/doi.org\/10.1212\/WNL.0000000000200150 (2022).","journal-title":"Neurology"},{"key":"94740_CR10","unstructured":"https:\/\/www.stepstone.at\/e-recruiting\/blog\/durchschnittsgehalt-oesterreich-stepstone-gehaltsreport\/#h-durchschnittsgehalt-in-osterreich-2023, <https:\/\/www.stepstone.at\/e-recruiting\/blog\/durchschnittsgehalt-oesterreich-stepstone-gehaltsreport\/#h-durchschnittsgehalt-in-osterreich-2023> (2024)."},{"key":"94740_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1046\/j.1468-1331.2003.00758.x","volume":"11","author":"E Pucci","year":"2004","unstructured":"Pucci, E., Cartechini, E., Taus, C. & Giuliani, G. Why physicians need to look more closely at the use of complementary and alternative medicine by multiple sclerosis patients. Eur. J. Neurol. 11, 263\u2013267. https:\/\/doi.org\/10.1046\/j.1468-1331.2003.00758.x (2004).","journal-title":"Eur. J. Neurol."},{"key":"94740_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102041","volume":"41","author":"E Silbermann","year":"2020","unstructured":"Silbermann, E. et al. Cross-sectional survey of complementary and alternative medicine used in Oregon and Southwest Washington to treat multiple sclerosis: A 17-Year update. Mult. Scler. Relat. Disord. 41, 102041. https:\/\/doi.org\/10.1016\/j.msard.2020.102041 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"94740_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1089\/acm.2017.0268","volume":"24","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Complementary and alternative medicine usage by multiple sclerosis patients: Results from a prospective clinical study. J. Altern. Complement Med. 24, 596\u2013602. https:\/\/doi.org\/10.1089\/acm.2017.0268 (2018).","journal-title":"J. Altern. Complement Med."},{"key":"94740_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1055\/s-2007-996363","volume":"65","author":"M Winterholler","year":"1997","unstructured":"Winterholler, M., Erbguth, F. & Neundorfer, B. The use of alternative medicine by multiple sclerosis patients\u2013patient characteristics and patterns of use. Fortschr. Neurol. Psychiatr. 65, 555\u2013561. https:\/\/doi.org\/10.1055\/s-2007-996363 (1997).","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"94740_CR15","first-page":"s151","volume":"22","author":"GM Owens","year":"2016","unstructured":"Owens, G. M. Economic burden of multiple sclerosis and the role of managed sare organizations in multiple sclerosis management. Am. J. Manag. Care 22, s151-158 (2016).","journal-title":"Am. J. Manag. Care"},{"key":"94740_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s40120-023-00549-7","volume":"12","author":"SD Newsome","year":"2023","unstructured":"Newsome, S. D., Binns, C., Kaunzner, U. W., Morgan, S. & Halper, J. No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: Clinician and patient perspectives [Narrative Review]. Neurol. Ther. 12, 1909\u20131935. https:\/\/doi.org\/10.1007\/s40120-023-00549-7 (2023).","journal-title":"Neurol. Ther."},{"key":"94740_CR17","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s13311-017-0566-3","volume":"14","author":"DM Hartung","year":"2017","unstructured":"Hartung, D. M. Economics and cost-effectiveness of multiple sclerosis therapies in the USA. Neurotherapeutics 14, 1018\u20131026. https:\/\/doi.org\/10.1007\/s13311-017-0566-3 (2017).","journal-title":"Neurotherapeutics"},{"key":"94740_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102647","volume":"19","author":"T Moser","year":"2020","unstructured":"Moser, T., Akgun, K., Proschmann, U., Sellner, J. & Ziemssen, T. The role of TH17 cells in multiple sclerosis: Therapeutic implications. Autoimmun. Rev. 19, 102647. https:\/\/doi.org\/10.1016\/j.autrev.2020.102647 (2020).","journal-title":"Autoimmun. Rev."},{"key":"94740_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield, A. L. & Hauser, S. L. B-cell therapy for multiple sclerosis: Entering an era. Ann. Neurol. 83, 13\u201326. https:\/\/doi.org\/10.1002\/ana.25119 (2018).","journal-title":"Ann. Neurol."},{"key":"94740_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12889-019-6907-x","volume":"19","author":"JM Garcia-Dominguez","year":"2019","unstructured":"Garcia-Dominguez, J. M. et al. Economic burden of multiple sclerosis in a population with low physical disability. BMC Public Health 19, 609. https:\/\/doi.org\/10.1186\/s12889-019-6907-x (2019).","journal-title":"BMC Public Health"},{"key":"94740_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/1352458517708672","volume":"23","author":"C Oreja-Guevara","year":"2017","unstructured":"Oreja-Guevara, C. et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain. Mult. Scler. 23, 166\u2013178. https:\/\/doi.org\/10.1177\/1352458517708672 (2017).","journal-title":"Mult. Scler."},{"key":"94740_CR22","doi-asserted-by":"publisher","first-page":"1053515","DOI":"10.3389\/fpubh.2022.1053515","volume":"10","author":"R Palladino","year":"2022","unstructured":"Palladino, R. et al. Multimorbidity and out-of-pocket expenditure on medicine in Europe: Longitudinal analysis of 13 European countries between 2013 and 2015. Front Public Health 10, 1053515. https:\/\/doi.org\/10.3389\/fpubh.2022.1053515 (2022).","journal-title":"Front Public Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94740-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94740-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94740-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T14:23:59Z","timestamp":1742394239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94740-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94740"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94740-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.T. has received consultancy fees from Arvelle Therapeutics, Argenx, Clexio, Celegene, UCB Pharma, Eisai, Epilog, Bial, Medtronic, Everpharma, Biogen, Takeda, Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals, and Marinus; speaker fees from Arvelle Therapeutics, Bial, Biogen, B\u00f6hringer Ingelheim, Eisai, Everpharma, GSK, GW Pharmaceuticals, Hikma, Liva-Nova, Newbridge, Novartis, Sanofi, Sandoz and UCB Pharma; research funding (directly, or to his institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer, and UCB Pharma outside the submitted work. He has received grants from Austrian Science Fund (FWF), \u00d6sterreichische Nationalbank, and the European Union. E.T. is the CEO of Neuroconsult Ges.m.b.H. P.W. has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Alexion, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva-Ratiopharm, Janssen-Pharmazeutika, Bristol-Myers SQUIBB and Horizon Therapeutics. T.M. received travel support, honoraria for presentations or participation on advisory boards from Biogen, BMS, Novartis, Roche, Sanofi, Merck and Teva. The remaining authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9469"}}